High-throughput Biomarker Analysis Delivers Maximum Information from Each Sample
News Jun 11, 2009
At the recent Biomarker World Congress 2009, held in Philadelphia, USA, 27 – 29 May, Dr Craig Stovold, Senior Project Manager-Bioanalytical Sciences, Quotient Bioresearch, reported on how the company’s multiplexed assays are delivering more data, on a greater number of analytes and in a shorter time; getting as much information as possible from each sample.
The increasing importance of biomarkers poses a number of challenges for the analytical laboratory. A large panel of biomarkers is often required to fully characterize a disease state and drug efficacy for a given condition. Ethical considerations and the requirements for clinical safety testing may impose practical limits on the number of samples that can be collected.
Dr Stovold commented: “Quotient Bioresearch was one of the commercial pioneers of biomarker analysis for clinical studies and pharmaceutical licensing. We now provide a number of multiplexing methods that dramatically increase the throughput of biomarker analysis. These include LC-MS/MS for small and large molecules, Meso Scale Discovery (MSD™), and Gyrolab® - a miniaturized open-technology immunoassay platform.”
Now in its fifth year, the Biomarker World Congress is dedicated to biomarker research and implementation. In Philadelphia, more than 400 delegates from pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers, were able to share experience, foster collaborations, and evaluate emerging technologies.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE